These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 30103119)

  • 1. The influence of residue in the position of 116 on the inhibitory potency of TH588 for MTH1.
    Niu RJ; Zheng QC; Zhang HX
    J Mol Graph Model; 2018 Oct; 85():75-83. PubMed ID: 30103119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Chirality of Crizotinib on Its MTH1 Protein Inhibitory Activity: Insight from Molecular Dynamics Simulations and Binding Free Energy Calculations.
    Niu Y; Pan D; Shi D; Bai Q; Liu H; Yao X
    PLoS One; 2015; 10(12):e0145219. PubMed ID: 26677850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the molecular mechanism for the differential inhibitory activities of compounds against MTH1.
    Wang M; Zhou S; Chen Q; Wang L; Liang Z; Wang J
    Sci Rep; 2017 Jan; 7():40557. PubMed ID: 28074893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal Structures and Inhibitor Interactions of Mouse and Dog MTH1 Reveal Species-Specific Differences in Affinity.
    Narwal M; Jemth AS; Gustafsson R; Almlöf I; Warpman Berglund U; Helleday T; Stenmark P
    Biochemistry; 2018 Feb; 57(5):593-603. PubMed ID: 29281266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia.
    Pompsch M; Vogel J; Classen F; Kranz P; Iliakis G; Riffkin H; Brockmeier U; Metzen E
    BMC Cancer; 2018 Nov; 18(1):1190. PubMed ID: 30497423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Proliferation-Inhibitory and Apoptosis-Inducing Effects of Targeting MTH1 on Multiple Myeloma Cells].
    Wang X; Wu Y; Zhang L; Li YX; Han B; Shi X; Wang W; Wang LS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1598-1604. PubMed ID: 33067960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of human MTH1, a Nudix family hydrolase that selectively degrades oxidized purine nucleoside triphosphates.
    Mishima M; Sakai Y; Itoh N; Kamiya H; Furuichi M; Takahashi M; Yamagata Y; Iwai S; Nakabeppu Y; Shirakawa M
    J Biol Chem; 2004 Aug; 279(32):33806-15. PubMed ID: 15133035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MTH1 inhibitor TH588 is a microtubule-modulating agent that eliminates cancer cells by activating the mitotic surveillance pathway.
    Gul N; Karlsson J; Tängemo C; Linsefors S; Tuyizere S; Perkins R; Ala C; Zou Z; Larsson E; Bergö MO; Lindahl P
    Sci Rep; 2019 Oct; 9(1):14667. PubMed ID: 31604991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.
    Aristizabal Prada ET; Orth M; Nölting S; Spöttl G; Maurer J; Auernhammer C
    PLoS One; 2017; 12(5):e0178375. PubMed ID: 28542590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG.
    Rudd SG; Gad H; Sanjiv K; Amaral N; Hagenkort A; Groth P; Ström CE; Mortusewicz O; Berglund UW; Helleday T
    Cancer Res; 2020 Sep; 80(17):3530-3541. PubMed ID: 32312836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
    Gad H; Koolmeister T; Jemth AS; Eshtad S; Jacques SA; Ström CE; Svensson LM; Schultz N; Lundbäck T; Einarsdottir BO; Saleh A; Göktürk C; Baranczewski P; Svensson R; Berntsson RP; Gustafsson R; Strömberg K; Sanjiv K; Jacques-Cordonnier MC; Desroses M; Gustavsson AL; Olofsson R; Johansson F; Homan EJ; Loseva O; Bräutigam L; Johansson L; Höglund A; Hagenkort A; Pham T; Altun M; Gaugaz FZ; Vikingsson S; Evers B; Henriksson M; Vallin KS; Wallner OA; Hammarström LG; Wiita E; Almlöf I; Kalderén C; Axelsson H; Djureinovic T; Puigvert JC; Häggblad M; Jeppsson F; Martens U; Lundin C; Lundgren B; Granelli I; Jensen AJ; Artursson P; Nilsson JA; Stenmark P; Scobie M; Berglund UW; Helleday T
    Nature; 2014 Apr; 508(7495):215-21. PubMed ID: 24695224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive Oxygen Species Dictate the Apoptotic Response of Melanoma Cells to TH588.
    Wang JY; Jin L; Yan XG; Sherwin S; Farrelly M; Zhang YY; Liu F; Wang CY; Guo ST; Yari H; La T; McFarlane J; Lei FX; Tabatabaee H; Chen JZ; Croft A; Jiang CC; Zhang XD
    J Invest Dermatol; 2016 Nov; 136(11):2277-2286. PubMed ID: 27427486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MutT homologue 1 (MTH1) removes N6-methyl-dATP from the dNTP pool.
    Scaletti ER; Vallin KS; Bräutigam L; Sarno A; Warpman Berglund U; Helleday T; Stenmark P; Jemth AS
    J Biol Chem; 2020 Apr; 295(15):4761-4772. PubMed ID: 32144205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.
    Kawamura T; Kawatani M; Muroi M; Kondoh Y; Futamura Y; Aono H; Tanaka M; Honda K; Osada H
    Sci Rep; 2016 May; 6():26521. PubMed ID: 27210421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Directly Binding Rather than Induced-Fit Dominated Binding Affinity Difference in (S)- and (R)-Crizotinib Bound MTH1.
    Sun H; Chen P; Li D; Li Y; Hou T
    J Chem Theory Comput; 2016 Feb; 12(2):851-60. PubMed ID: 26764587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics and structural biology of human MutT homolog, MTH1.
    Nakabeppu Y
    Mutat Res; 2001 Jun; 477(1-2):59-70. PubMed ID: 11376687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TH588, an MTH1 inhibitor, enhances phenethyl isothiocyanate-induced growth inhibition in pancreatic cancer cells.
    Ikejiri F; Honma Y; Kasukabe T; Urano T; Suzumiya J
    Oncol Lett; 2018 Mar; 15(3):3240-3244. PubMed ID: 29435064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and development of MTH1 inhibitors for treatment of cancer.
    Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
    Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
    Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
    BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors.
    Samaranayake GJ; Troccoli CI; Zhang L; Huynh M; Jayaraj CJ; Ji D; McPherson L; Onishi Y; Nguyen DM; Robbins DJ; Karbaschi M; Cooke MS; Barrientos A; Kool ET; Rai P
    Mol Cancer Ther; 2020 Feb; 19(2):432-446. PubMed ID: 31744893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.